Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442397 | 0.87 | HPD (0.60) | HPDFLT1FLT4KDRKCNMA1 | |
| Hydrochloric Acid SCHEMBL11776053 | 0.85 | HPD (0.59) | HPDFLT1FLT4KDRKCNMA1 | |
| Ammonia Solution, Strong SCHEMBL28953061 | 0.85 | HPD (0.59) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL4658862 | 0.85 | HPD (0.62) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL2323726 | 0.85 | HPD (0.59) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL165527 | 0.85 | HPD (0.59) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL29079008 | 0.84 | HPD (0.58) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL4147867 | 0.83 | FLT1 (0.62) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL30959714 | 0.81 | CFTR (0.60) | HPDFLT1FLT4KDRKCNMA1 | |
| SCHEMBL22065390 | 0.81 | HPD (0.65) | HPDFLT1FLT4KDRKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7276487-B2 | 9a, 11-3C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7129221-B2 | 6,11-bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050090460-A1 | 9a,11-3C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030227-A1 | 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040053861-A1 | 6,11-Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053861-A1 | 6,11-Bicyclic erythromycin derivatives | ABCB11, CYP2B6, CYP2D6 | HPD 949/4885FLT1 2408/4885FLT4 3122/4885 |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | CYP3A7, CYP2C8, CYP51A1 | HPD 333/4885FLT1 3976/4885FLT4 4332/4885 |
| US-20050090460-A1 | 9a,11-3C-bicyclic 9a-azalide derivatives | CYP2C9, CYP2C19, UGT1A9 | HPD 229/4885FLT1 4263/4885FLT4 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.